US regulators laid out new guidelines for approving custom-made treatments for individual patients, a move that could bring ...
The FDA is expected to decide on treatments for asthma, chronic rhinosinusitis with nasal polyps, dyslipidemia, Cushing syndrome, gonorrhea, HSCT-associated thrombotic microangiopathy, marginal zone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback